Activity Overview
This online, on-demand virtual symposium brings together renowned experts in EGFR-mutated non–small cell lung cancer. In this educational program, these experts use real-world patient scenarios to examine adjuvant vs neoadjuvant therapy in an early-stage setting; evidence supporting monotherapy and combination regimens in frontline treatment, including chemotherapy and amivantamab-based regimens; and current and emerging options in common patient treatment journeys.
This educational activity is an archive of the live symposium held on February 19, 2026.
Target Audience
This educational activity is directed toward medical and thoracic oncologists, pulmonologists, pathologists, advanced practice providers, nurses, pharmacists, and other health care providers involved in the management of NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Interpret recent clinical trial safety and efficacy data for agents being studied in early-stage and advanced EGFR-mutated NSCLC
- Formulate appropriate strategies for the management of adverse effects related to EGFR-targeted therapies in advanced NSCLC
- Develop individualized first-line treatment plans for patients with early-stage and advanced EGFR-mutant NSCLC by implementing new data and guideline-recommended strategies
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here